Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Naviglobin** is a Navil Laboratories haematinic brand portfolio rather than one uniquely defined drug substance. The official portfolio includes Naviglobin Capsule, Naviglobin Drops, Naviglobin Syrup, and Naviglobin-P Syrup; these oral fixed-dose formulations differ in their active ingredients. Across formulations, they provide iron with folic acid and, depending on the presentation, cyanocobalamin, zinc, protein, vitamin C, copper, vitamin B6, vitamin D3, dried yeast, and dicalcium phosphate. Their intended pharmacological role is nutritional replacement to support erythropoiesis, haemoglobin formation, and prevention or treatment of iron- and folate-related anaemia. ([navillab.in](https://navillab.in/pharma-brands/naviglobin/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Naviglobin.